NDA 205394 · Gensco
Rizafilm
Rizatriptan Benzoate · Oral
Last checked: Nov 19, 2026Latest source record: Feb 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Apr 14, 2023
Approved uses
2
Original approval plus efficacy supplements
Registered trials
14
11 Phase 3, 1 recruiting
FAERS reports
1,646
1,034 serious, 34 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 28, 2026.
RizaFilm™ is indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age. Limitations of Use RizaFilm should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with RizaFilm, the diagnosis of migraine should be reconsidered before RizaFilm is administered to treat any subsequent attacks. RizaFilm is not indicated for the preventive treatment of migraine. Safety and effectiveness of RizaFilm have not been established for cluster headache. RizaFilm is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years of age (1) Limitations of Use : Use only after a clear diagnosis of migraine has been established (1) Not indicated for the preventive treatment of migraine (1) Not indicated for the treatment of cluster headache (1)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 26, 2026 Supplement 5 · Efficacy LabelLetter
- Apr 14, 2023 Original approval · Type 3 - New Dosage Form LabelLetterReview
2 products under this application
- RIZAFILM · RIZATRIPTAN BENZOATE EQ 5MG BASE · FILM, ORAL · Prescription
- RIZAFILM · RIZATRIPTAN BENZOATE EQ 10MG BASE · FILM, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rizatriptan Benzoate" as an intervention, any sponsor and status, largest first.
- MK0462 in Treatment of Migraine With Recurrence (MK0462-022)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00897949 · 1,473 participants · Start Mar 1995 · Primary completion Jan 1996
Drug: rizatriptan benzoate (MK0462); Comparator: placebo · For: Migraine Headache
- Rizatriptan 5 mg and 10 mg, Sumatriptan 100 mg, and Placebo Comparison Study (0462-030)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00898677 · 1,268 participants · Start Sep 1995 · Primary completion May 1996
Drug: rizatriptan benzoate; rizatriptan benzoate and 2 more · For: Migraine Headache
- MK0462 5 mg, Sumatriptan 50 mg, and Placebo Comparison Study (0462-029)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00897104 · 933 participants · Start Aug 1995 · Primary completion May 1996
Drug: rizatriptan benzoate (MK0462); Comparator: sumatriptan and 1 more · For: Migraine Headache
- A Study to Evaluate the Safety and Tolerability of Rizatriptan for Long Term Treatment of Acute Migraine in Children and Adolescents (MK-0462-086 AM3)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01004263 · 674 participants · Start Dec 1, 2009 · Primary completion Apr 18, 2011
Drug: rizatriptan benzoate · For: Acute Migraine With or Without Aura in Adolescents
- Study to Test an Approved Product in the Early Treatment of Migraine (0462-065)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00092963 · 529 participants · Start Aug 17, 2004 · Primary completion Jan 14, 2005
Drug: MK0462, rizatriptan benzoate / Duration of Treatment: 1day; Comparator: placebo / Duration of Treatment: 1 day · For: Migraine
- Treatment of Multiple Attacks of Acute Migraine (0462-025)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00899379 · 473 participants · Start Apr 1995 · Primary completion Jan 1996
Drug: rizatriptan benzoate; Comparator: Placebo · For: Migraine Headache
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-071)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00111709 · 393 participants · Start May 27, 2005 · Primary completion Feb 24, 2006
Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1 day; Comparator: placebo / Duration of Treatment - 1 day · For: Migraine
- Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00111722 · 393 participants · Start May 27, 2005 · Primary completion Feb 15, 2006
Drug: MK0462, rizatriptan benzoate / Duration of Treatment -1day; Comparator: placebo / Duration of Treatment - 1 day · For: Migraine
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective420
- headache259
- off label use247
- nausea239
- migraine204
- product use in unapproved indication178
- drug intolerance175
- hypersensitivity169
- fatigue140
- swelling face132
- angioedema128
- dysphonia128
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 4 |
| 2005 | 7 |
| 2006 | 3 |
| 2007 | 21 |
| 2008 | 31 |
| 2009 | 28 |
| 2010 | 15 |
| 2011 | 20 |
| 2012 | 15 |
| 2013 | 42 |
| 2014 | 36 |
| 2015 | 32 |
| 2016 | 65 |
| 2017 | 61 |
| 2018 | 96 |
| 2019 | 131 |
| 2020 | 113 |
| 2021 | 118 |
| 2022 | 159 |
| 2023 | 152 |
| 2024 | 166 |
| 2025 | 189 |
| 2026 | 142 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- A novel rizatriptan oral gel formulation: Bioavailability and bioequivalence.
Tellone V, Dragone P, Picollo R, et al. · Int J Clin Pharmacol Ther 2020 · Randomized Controlled Trial
- Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents.
Sun H, Bastings E, Temeck J, et al. · JAMA Pediatr 2013 · Meta-Analysis, Systematic Review
Sponsor: Gensco
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.